Medical Countermeasures Strategic Planning and Committees
ASPR has both important policy and operational responsibilities related to the advanced research and development and procurement of medical countermeasures (MCMs). Within ASPR, BARDA provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, and nuclear accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases.
In addition, ASPR leads federal coordination efforts to enhance chemical, biological, radiological and nuclear threats and emerging infectious diseases preparedness from a medical countermeasure perspective through the Public Health Emergency Medical Countermeasures Enterprise and ASPR coordinates the National Biodefense Science Board.
Strategic Planning
2023 HHS Screening Framework Guidance for Providers and Users of Synthetic Nucleic Acids
S3
National Influenza Vaccine Modernization Strategy
2020-2030
NIVMS
Stewardship and Access
Plan Development Guide:
Combating Antibiotic-Resistant Bacteria 2021
SAP
National Biodefense Strategy and Implementation Plan
2022
NBS
Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation
Plan (SIP) 2024
PHEMCE
BARDA Pandemic Influenza Preparedness and Response Strategy
BARDA
Boards and Committees
PHEMCE: Public Health Emergency Medical Countermeasures Enterprise
NBSB: National Biodefense Science Board
